 |
 |
 |
 |
 |
|
|||||
|
Read more about your physician...
Back Page
| Cranmer,Lee Assistant Professor,MD, PhD Therapeutic Development |
 |
|||
| Address: Arizona Cancer Center P.O. Box 245024 Work Phone: 520-626-0501 Fax Number: 520-626-2225 Email: mailto:lcranmer@azcc.arizona.edu |
||||
Biography:
Dr. Cranmer grew up in Southern California. After completing undergraduate studies in Biochemistry at Harvard University, he obtained a Master of Science degree in parasitology from the University of Liverpool/Liverpool School of Topical Medicine in England. Thereafter, he enrolled in the Medical Scientist Training Program at the University of California, San Diego. While there, Dr. Cranmer was supported by a Life and Health Insurance Medical Research Fund scholarship. His graduate research was in the area of viral immunology, with an emphasis on the design of experimental vaccines. After receiving his M.D. and Ph.D in Biology in 1998, Dr. Cranmer completed a residency in internal medicine at the Mayo Clinic in Rochester, Minnesota. He then came to the Arizona Cancer Center at the University of Arizona to complete fellowship training in medical oncology. It was at the Arizona Cancer Center that Dr. Cranmer began his collaboration with Dr. Evan Hersh in the Melanoma Program. After completion of his training in 2003, Dr. Cranmer remained at the Arizona Cancer Center as a faculty member. He works closely with Dr. Hersh in treating patients with malignant melanoma. Dr. Cranmer is also developing interdisciplinary collaborations in the management of sarcomas, an area in which he has developed a strong interest. Dr. Cranmer also treats patients with general hematologic and oncologic disorders, attends hospital in-patients, and provides outside consultation in clinical drug development, malignant melanoma and sarcoma management. |
||||
| Summary of Research Activity: Dr. Cranmer has strong clinical and basic research programs. He is primary investigator on a number of research protocols in malignant melanoma and is developing protocols for patients with sarcomas. He also has a strong interest in the biology of brain metastasis in melanoma, a significant clinical problem. Dr. Cranmer collaborates closely with Dr. Katrina Trevor, Ph.D. in basic research and basic science investigations. His two areas of focus are biology of brain metastasis in melanoma and the pathogenesis of synovial sarcoma. |
||||
| Selected Publications:
Ebbinghaus, S., Rubin, E., Hersh, E., Cranmer, L.D., Bonate, P.L., Fram, R.J., Jekunen, A., Weitman, S., and Hammond, L.A. A Phase I Study of Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors. (2005) Clin Cancer Res 11(21) 7807-7816. Cranmer, L.D., Bandlamuri S., Trevor K., and Hersh E. Rodent models of brain metastasis in melanoma. (2005) Melanoma Res 5:325-356. Ebbinghaus, S., Rubin, E., Hersh, E., Cranmer, LD, Marsh, S., Bonate, P., Van Dijk, S., Fram, R., and Jekunen, A. A phase I study of ILX-651 administered intravenously daily for five days every three weeks in patients with advanced solid tumors. Proceedings American Society of Clinical Oncology (2003). 22: page 129, 2003 (abstr 517). Cranmer, LD, Warrington, K., and Ytterberg, S. 61-year-old man with dyspnea and bilateral foot drop. Mayo Clinic Proceedings. (2002) 77(4):363-366. Morello, C.S., Cranmer, LD, and Spector, D.H. Suppresion of murine cytomegalovirus (MCMV) infection with a DNA vaccine encoding MCMV M84 (a homolog of human cytomaglovirus pp65). Journal of Virology (2000) 74(8): 3696-3708. Gonzalez-Armas, J.C., Morello, C.S., Cranmer, LD and Spector, D.H. DNA immunization confers protection against murine cytomegalovirus infection. Journal of Virology (1996)70(11):7921-7928. |
||||
| Collaborative Research: |
||||